Cipla partners with Hetero to roll out biosimilar drug ‘Darbepoetin alfa’
Cipla, a global healthcare company which uses technology and innovation to meet every day needs of all patients announced a […]
Say something
Tags: biology, Biosimilar, biosimilar product, biosimilar products, blood transfusions, Business Partnership, Chief Medical Officer, China, chronic kidney disease, Cipla, CIPLA LIMITED, darbepoetin alfa, Dialysis, Erythropoiesis-stimulating agents, Erythropoietin, Health/Medical/Pharmaceuticals, healthcare, India, Jaideep Gogtay, medicine, Pharmacology, renal replacement therapy, renal transplant, Rs, treatment for anaemia associated with chronic kidney disease
Swap Transplant Brings New Hope to Kidney Patients
If the blood group of the donor of one pair matches that of the recipient of another pair, it can […]
-
-
Flipkart Health+ App Launched
06-04-2022
